Recognition of viral single-stranded RNA by Toll-like receptors

Advanced Drug Delivery Reviews

Volumn 60, Issue 7, 2008, Pages 813-823

  Diebold, Sandra S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant; Dendritic cells; Immune response modifiers; Innate immunity; Pathogen associated molecular patterns; Pattern recognition receptors; Toll like receptors; Virus

Indexed keywords

ADJUVANTS; DENDRITIC CELLS; IMMUNE RESPONSE MODIFIERS; INNATE IMMUNITY; PATHOGEN ASSOCIATED MOLECULAR PATTERNS; PATTERN RECOGNITION RECEPTORS; TOLL LIKE RECEPTORS;

DISEASES; IMMUNOLOGY; LIGANDS; RNA; VIRUSES;

PATTERN RECOGNITION;

IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; LIGAND; OLIGODESOXYRIBONUCLEOTIDE; OLIGORIBONUCLEOTIDE; RESIQUIMOD; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BASAL CELL CARCINOMA; CELL TYPE; COMPREHENSION; CONDYLOMA ACUMINATUM; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; INTERVENTION STUDY; MAMMAL; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TUMOR; VIRUS; VIRUS INTERFERENCE;

ANIMALS; HUMANS; IMMUNOTHERAPY; LIGANDS; RNA, VIRAL; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTORS;

EID: 41349095198     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.11.004     Document Type: Review

References (122)

1. Janeway Jr. C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54 1 (1989) 1-13
2. Kawai T., and Akira S. Innate immune recognition of viral infection. Nat. Immunol. 7 (2006) 131-137
3. Pichlmair A., and Reis e Sousa C. Innate recognition of viruses. Immunity 27 (2007) 370-383
4. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., and Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5 (2004) 730-737
5. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., Foy E., Loo Y.M., Gale Jr. M., Akira S., Yonehara S., Kato A., and Fujita T. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol. 175 (2005) 2851-2858
6. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., Yamaguchi O., Otsu K., Tsujimura T., Koh C.S., Reis e Sousa C., Matsuura Y., Fujita T., and Akira S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 (2006) 101-105
7. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., Lu Y., Miyagishi M., Kodama T., Honda K., Ohba Y., and Taniguchi T. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 (2007) 501-505
8. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001) 778-809 table of contents
9. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr. Opin. Immunol. 16 (2004) 21-25
10. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560 (2005) 11-18
11. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
12. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004) 1529-1531
13. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., and Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
14. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
15. Lund J., Sato A., Akira S., Medzhitov R., and Iwasaki A. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198 (2003) 513-520
16. Jurk M., Heil F., Vollmer J., Schetter C., Krieg A.M., Wagner H., Lipford G., and Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3 (2002) 499
17. Jurk M., Kritzler A., Schulte B., Tluk S., Schetter C., Krieg A.M., and Vollmer J. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur. J. Immunol. 36 (2006) 1815-1826
18. Gorden K.K., Qiu X.X., Binsfeld C.C., Vasilakos J.P., and Alkan S.S. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J. Immunol. 177 (2006) 6584-6587
19. Zhang H., Tay P.N., Cao W., Li W., and Lu J. Integrin-nucleated Toll-like receptor (TLR) dimerization reveals subcellular targeting of TLRs and distinct mechanisms of TLR4 activation and signaling. FEBS. Lett. 532 (2002) 171-176
20. Lee J., Chuang T.H., Redecke V., She L., Pitha P.M., Carson D.A., Raz E., and Cottam H.B. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6646-6651
21. Matsumoto M., Funami K., Tanabe M., Oshiumi H., Shingai M., Seto Y., Yamamoto A., and Seya T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J. Immunol. 171 (2003) 3154-3162
22. Funami K., Matsumoto M., Oshiumi H., Akazawa T., Yamamoto A., and Seya T. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int. Immunol. 16 (2004) 1143-1154
23. Latz E., Schoenemeyer A., Visintin A., Fitzgerald K.A., Monks B.G., Knetter C.F., Lien E., Nilsen N.J., Espevik T., and Golenbock D.T. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5 (2004) 190-198
24. Nishiya T., and DeFranco A.L. Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J. Biol. Chem. 279 (2004) 19008-19017
25. Nishiya T., Kajita E., Miwa S., and Defranco A.L. TLR3 and TLR7 are targeted to the same intracellular compartments by distinct regulatory elements. J. Biol. Chem. 280 (2005) 37107-37117
26. Barton G.M., Kagan J.C., and Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 7 (2006) 49-56
27. Gardai S.J., Bratton D.L., Ogden C.A., and Henson P.M. Recognition ligands on apoptotic cells: a perspective. J. Leukoc. Biol. 79 (2006) 896-903
28. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., Azuma Y.T., Flavell R.A., Liljestrom P., and Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 (2005) 887-892
29. Edwards A.D., Diebold S.S., Slack E.M., Tomizawa H., Hemmi H., Kaisho T., Akira S., and Reis e Sousa C. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur. J. Immunol. 33 (2003) 827-833
30. Guzylack-Piriou L., Bergamin F., Gerber M., McCullough K.C., and Summerfield A. Plasmacytoid dendritic cell activation by foot-and-mouthdisease virus requires immune complexes. Eur. J. Immunol. 36 (2006) 1674-1683
31. Lee H.K., Lund J.M., Ramanathan B., Mizushima N., and Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315 (2007) 1398-1401
32. Wang J.P., Asher D.R., Chan M., Kurt-Jones E.A., and Finberg R.W. Cutting edge: antibody-mediated TLR7-dependent recognition of viral RNA. J. Immunol. 178 (2007) 3363-3367
33. Nolte M.A., Leibundgut-Landmann S., Joffre O., and Reis e Sousa C. Dendritic cell quiescence during systemic inflammation driven by LPS stimulation of radioresistant cells in vivo. J. Exp. Med. 204 (2007) 1487-1501
34. Steinman R.M., and Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311 (2006) 17-58
35. Miettinen M., Sareneva T., Julkunen I., and Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes. Immun. 2 (2001) 349-355
36. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
37. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4 (2003) 1009-1015
38. Durand V., Wong S.Y., Tough D.F., and Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol. Cell. Biol. 82 (2004) 596-602
39. Le Bon A., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., and Tough D.F. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176 (2006) 2074-2078
40. Izaguirre A., Barnes B.J., Amrute S., Yeow W.S., Megjugorac N., Dai J., Feng D., Chung E., Pitha P.M., and Fitzgerald-Bocarsly P. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74 (2003) 1125-1138
41. Kerkmann M., Rothenfusser S., Hornung V., Towarowski A., Wagner M., Sarris A., Giese T., Endres S., and Hartmann G. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J. Immunol. 170 (2003) 4465-4474
42. Prakash A., and Levy D.E. Regulation of IRF7 through cell type-specific protein stability. Biochem. Biophys. Res. Commun. 342 (2006) 50-56
43. Honda K., Ohba Y., Yanai H., Negishi H., Mizutani T., Takaoka A., Taya C., and Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434 (2005) 1035-1040
44. Takaoka A., Yanai H., Kondo S., Duncan G., Negishi H., Mizutani T., Kano S., Honda K., Ohba Y., Mak T.W., and Taniguchi T. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434 (2005) 243-249
45. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., Tomai M.A., Alkan S.S., and Vasilakos J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174 (2005) 1259-1268
46. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., and Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204 (2007) 1441-1451
47. Hart O.M., Athie-Morales V., O'Connor G.M., and Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J. Immunol. 175 (2005) 1636-1642
48. Gorski K.S., Waller E.L., Bjornton-Severson J., Hanten J.A., Riter C.L., Kieper W.C., Gorden K.B., Miller J.S., Vasilakos J.P., Tomai M.A., and Alkan S.S. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int. Immunol. 18 (2006) 1115-1126
49. Sawaki J., Tsutsui H., Hayashi N., Yasuda K., Akira S., Tanizawa T., and Nakanishi K. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int. Immunol. 19 (2007) 311-320
50. Alter G., Suscovich T.J., Teigen N., Meier A., Streeck H., Brander C., and Altfeld M. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J. Immunol. 178 (2007) 7658-7666
51. Girart M.V., Fuertes M.B., Domaica C.I., Rossi L.E., and Zwirner N.W. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J. Immunol. 179 (2007) 3472-3479
52. Nagase H., Okugawa S., Ota Y., Yamaguchi M., Tomizawa H., Matsushima K., Ohta K., Yamamoto K., and Hirai K. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J. Immunol. 171 (2003) 3977-3982
53. Hattermann K., Picard S., Borgeat M., Leclerc P., Pouliot M., and Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. Faseb J. 21 (2007) 1575-1585
54. Matsushima H., Yamada N., Matsue H., and Shimada S. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells. J. Immunol. 173 (2004) 531-541
55. Heib V., Becker M., Warger T., Rechtsteiner G., Tertilt C., Klein M., Bopp T., Taube C., Schild H., Schmitt E., and Stassen M. Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 110 (2007) 946-953
56. Bourke E., Bosisio D., Golay J., Polentarutti N., and Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102 (2003) 956-963
57. Bekeredjian-Ding I.B., Wagner M., Hornung V., Giese T., Schnurr M., Endres S., and Hartmann G. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174 (2005) 4043-4050
58. Heer A.K., Shamshiev A., Donda A., Uematsu S., Akira S., Kopf M., and Marsland B.J. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178 (2007) 2182-2191
59. + regulatory T cell function. Science 309 (2005) 1380-1384
60. Peng G., Wang H.Y., Peng W., Kiniwa Y., Seo K.H., and Wang R.F. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27 (2007) 334-348
61. Gunzer M., Riemann H., Basoglu Y., Hillmer A., Weishaupt C., Balkow S., Benninghoff B., Ernst B., Steinert M., Scholzen T., Sunderkotter C., and Grabbe S. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 106 (2005) 2424-2432
62. Triantafilou K., Orthopoulos G., Vakakis E., Ahmed M.A., Golenbock D.T., Lepper P.M., and Triantafilou M. Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent. Cell Microbiol. 7 (2005) 1117-1126
63. Triantafilou K., Vakakis E., Orthopoulos G., Ahmed M.A., Schumann C., Lepper P.M., and Triantafilou M. TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1. Eur. J. Immunol. 35 (2005) 2416-2423
64. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., and Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3 (2002) 196-200
65. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., Iwasaki A., and Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5598-5603
66. Beignon A.S., McKenna K., Skoberne M., Manches O., DaSilva I., Kavanagh D.G., Larsson M., Gorelick R.J., Lifson J.D., and Bhardwaj N. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115 (2005) 3265-3275
67. Wang J.P., Liu P., Latz E., Golenbock D.T., Finberg R.W., and Libraty D.H. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J. Immunol. 177 (2006) 7114-7121
68. Barchet W., Krug A., Cella M., Newby C., Fischer J.A., Dzionek A., Pekosz A., and Colonna M. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur. J. Immunol. 35 (2005) 236-242
69. Pichlmair A., Schulz O., Tan C.P., Naslund T.I., Liljestrom P., Weber F., and Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314 (2006) 997-1001
70. Melchjorsen J., Jensen S.B., Malmgaard L., Rasmussen S.B., Weber F., Bowie A.G., Matikainen S., and Paludan S.R. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J. Virol. 79 (2005) 12944-12951
71. Koyama S., Ishii K.J., Kumar H., Tanimoto T., Coban C., Uematsu S., Kawai T., and Akira S. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179 (2007) 4711-4720
72. Cervantes-Barragan L., Zust R., Weber F., Spiegel M., Lang K.S., Akira S., Thiel V., and Ludewig B. Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. Blood 109 (2007) 1131-1137
73. Finlay B.B., and McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124 (2006) 767-782
74. Schlender J., Hornung V., Finke S., Gunthner-Biller M., Marozin S., Brzozka K., Moghim S., Endres S., Hartmann G., and Conzelmann K.K. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J. Virol. 79 (2005) 5507-5515
75. Abe T., Kaname Y., Hamamoto I., Tsuda Y., Wen X., Taguwa S., Moriishi K., Takeuchi O., Kawai T., Kanto T., Hayashi N., Akira S., and Matsuura Y. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J. Virol. 81 (2007) 8953-8966
76. Martin H.J., Lee J.M., Walls D., and Hayward S.D. Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J. Virol. 81 (2007) 9748-9758
77. Schoenemeyer A., Barnes B.J., Mancl M.E., Latz E., Goutagny N., Pitha P.M., Fitzgerald K.A., and Golenbock D.T. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem. 280 (2005) 17005-17012
78. Martinelli E., Cicala C., Van Ryk D., Goode D.J., Macleod K., Arthos J., and Fauci A.S. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3396-3401
79. Chuang T.H., and Ulevitch R.J. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur. Cytokine Netw. 11 (2000) 372-378
80. Du X., Poltorak A., Wei Y., and Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur. Cytokine Netw. 11 (2000) 362-371
81. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., and Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11 (2005) 263-270
82. Diebold S.S., Massacrier C., Akira S., Paturel C., Morel Y., and Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur. J. Immunol. 36 (2006) 3256-3267
83. Meier A., Alter G., Frahm N., Sidhu H., Li B., Bagchi A., Teigen N., Streeck H., Stellbrink H.J., Hellman J., van Lunzen J., and Altfeld M. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J. Virol. 81 (2007) 8180-8191
84. Heil F., Ahmad-Nejad P., Hemmi H., Hochrein H., Ampenberger F., Gellert T., Dietrich H., Lipford G., Takeda K., Akira S., Wagner H., and Bauer S. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur. J. Immunol. 33 (2003) 2987-2997
85. Lan T., Kandimalla E.R., Yu D., Bhagat L., Li Y., Wang D., Zhu F., Tang J.X., Putta M.R., Cong Y., Trombino A.F., Sullivan T., and Agrawal S. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13750-13755
86. Bernstein D.I., Miller R.L., and Harrison C.J. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J. Infect. Dis. 167 (1993) 731-735
87. Spruance S.L., Tyring S.K., Smith M.H., and Meng T.C. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. 184 (2001) 196-200
88. von Krogh G., Lacey C.J., Gross G., Barrasso R., and Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex. Transm. Infect. 76 (2000) 162-168
89. Nair S., McLaughlin C., Weizer A., Su Z., Boczkowski D., Dannull J., Vieweg J., and Gilboa E. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171 (2003) 6275-6282
90. Palamara F., Meindl S., Holcmann M., Luhrs P., Stingl G., and Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 173 (2004) 3051-3061
91. Fleming C.J., Bryden A.M., Evans A., Dawe R.S., and Ibbotson S.H. A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br. J. Dermatol. 151 (2004) 485-488
92. Gollnick H., Barona C.G., Frank R.G., Ruzicka T., Megahed M., Tebbs V., Owens M., and Stampone P. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur. J. Dermatol. 15 (2005) 374-381
93. Peris K., Campione E., Micantonio T., Marulli G.C., Fargnoli M.C., and Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol. Surg. 31 (2005) 318-323
94. Pockros P.J., Guyader D., Patton H., Tong M.J., Wright T., McHutchison J.G., and Meng T.C. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 47 (2007) 174-182
95. Schon M.P., Schon M., and Klotz K.N. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J. Invest. Dermatol. 126 (2006) 1338-1347
96. Ohta A., and Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414 (2001) 916-920
97. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348 (2005) 1079-1090
98. Kariko K., Buckstein M., Ni H., and Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005) 165-175
99. Robbins M., Judge A., Liang L., McClintock K., Yaworski E., and Maclachlan I. 2′-O-methyl-modified RNAs Act as TLR7 Antagonists. Mol. Ther. 15 (2007) 1663-1669
100. Sioud M., Furset G., and Cekaite L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem. Biophys. Res. Commun. 361 (2007) 122-126
101. Tan E.M., Chan E.K., Sullivan K.F., and Rubin R.L. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin. Immunol. Immunopathol. 47 (1988) 121-141
102. Yurasov S., Wardemann H., Hammersen J., Tsuiji M., Meffre E., Pascual V., and Nussenzweig M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201 (2005) 703-711
103. Samuels J., Ng Y.S., Coupillaud C., Paget D., and Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201 (2005) 1659-1667
104. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 (2002) 603-607
105. Lau C.M., Broughton C., Tabor A.S., Akira S., Flavell R.A., Mamula M.J., Christensen S.R., Shlomchik M.J., Viglianti G.A., Rifkin I.R., and Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202 (2005) 1171-1177
106. Plotz P.H. The autoantibody repertoire: searching for order. Nat. Rev. Immunol. 3 (2003) 73-78
107. Marshak-Rothstein A., and Rifkin I.R. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu. Rev. Immunol. 25 (2007) 419-441
108. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., Chang B., Duramad O., and Coffman R.L. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202 (2005) 1131-1139
109. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., Akira S., Kelly K.M., Reeves W.H., Bauer S., and Krieg A.M. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202 (2005) 1575-1585
110. Savarese E., Chae O.W., Trowitzsch S., Weber G., Kastner B., Akira S., Wagner H., Schmid R.M., Bauer S., and Krug A. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107 (2006) 3229-3234
111. Yasuda K., Richez C., Maciaszek J.W., Agrawal N., Akira S., Marshak-Rothstein A., and Rifkin I.R. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 178 (2007) 6876-6885
112. Ronnblom L., Eloranta M.L., and Alm G.V. Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 36 (2003) 463-472
113. Pascual V., Banchereau J., and Palucka A.K. The central role of dendritic cells and interferon-alpha in SLE. Curr. Opin. Rheumatol. 15 (2003) 548-556
114. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., and Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25 (2006) 417-428
115. Berland R., Fernandez L., Kari E., Han J.H., Lomakin I., Akira S., Wortis H.H., Kearney J.F., Ucci A.A., and Imanishi-Kari T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25 (2006) 429-440
116. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., and Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312 (2006) 1669-1672
117. Berghofer B., Frommer T., Haley G., Fink L., Bein G., and Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177 (2006) 2088-2096
118. Krieg A.M., Wu T., Weeratna R., Efler S.M., Love-Homan L., Yang L., Yi A.K., Short D., and Davis H.L. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12631-12636
119. Yamada H., Gursel I., Takeshita F., Conover J., Ishii K.J., Gursel M., Takeshita S., and Klinman D.M. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol. 169 (2002) 5590-5594
120. Stunz L.L., Lenert P., Peckham D., Yi A.K., Haxhinasto S., Chang M., Krieg A.M., and Ashman R.F. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 32 (2002) 1212-1222
121. Ho P.P., Fontoura P., Ruiz P.J., Steinman L., and Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J. Immunol. 171 (2003) 4920-4926
122. Gorden K.K., Qiu X., Battiste J.J., Wightman P.P., Vasilakos J.P., and Alkan S.S. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J. Immunol. 177 (2006) 8164-8170